177 related articles for article (PubMed ID: 9918413)
1. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
2. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
3. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
4. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
5. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Lambin P; Guichard M; Chavaudra N; Malaise EP
Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
[TBL] [Abstract][Full Text] [Related]
6. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
7. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
Lartigau E; Guichard M
Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
[TBL] [Abstract][Full Text] [Related]
8. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
Zeman EM; Lemmon MJ; Brown JM
Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
[TBL] [Abstract][Full Text] [Related]
9. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
11. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
12. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
Zeman EM; Brown JM
Int J Radiat Biol; 1991 Jan; 59(1):117-31. PubMed ID: 1671059
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
15. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
16. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
Patterson AV; Robertson N; Houlbrook S; Stephens MA; Adams GE; Harris AL; Stratford IJ; Carmichael J
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):369-72. PubMed ID: 8195035
[TBL] [Abstract][Full Text] [Related]
17. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
19. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
Shin HJ; Kim JY; Yoo CW; Roberts SA; Lee S; Choi SJ; Lee HY; Lee DH; Kim TH; Cho KH
J Cancer Res Clin Oncol; 2008 Mar; 134(3):397-404. PubMed ID: 17724612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
